Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016.
Journal
Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
accepted:
14
11
2019
pubmed:
15
2
2020
medline:
15
5
2020
entrez:
15
2
2020
Statut:
ppublish
Résumé
Most countries use 3-dose pneumococcal conjugate vaccine (PCV) schedules; a 4-dose (3 primary and 1 booster) schedule is licensed for US infants. We evaluated the invasive pneumococcal disease (IPD) breakthrough infection incidence in children receiving 2 vs 3 primary PCV doses with and without booster doses (2 + 1 vs 3 + 1; 2 + 0 vs 3 + 0). We used 2001-2016 Active Bacterial Core surveillance data to identify breakthrough infections (vaccine-type IPD in children receiving ≥1 7-valent pneumococcal conjugate vaccine [PCV7] or 13-valent pneumococcal conjugate vaccine [PCV13] dose) among children aged <5 years. We estimated schedule-specific IPD incidence rates (IRs) per 100 000 person-years and compared incidence by schedule (2 + 1 vs 3 + 1; 2 + 0 vs 3 + 0) using rate differences (RDs) and incidence rate ratios. We identified 71 PCV7 and 49 PCV13 breakthrough infections among children receiving a schedule of interest. PCV13 breakthrough infection rates were higher in children aged <1 year receiving the 2 + 0 (IR: 7.8) vs 3 + 0 (IR: 0.6) schedule (incidence rate ratio: 12.9; 95% confidence interval: 4.1-40.4); PCV7 results were similar. Differences in PCV13 breakthrough infection rates by schedule in children aged <1 year were larger in 2010-2011 (2 + 0 IR: 18.6; 3 + 0 IR: 1.4; RD: 16.6) vs 2012-2016 (2 + 0 IR: 3.6; 3 + 0 IR: 0.2; RD: 3.4). No differences between schedules were detected in children aged ≥1 year for PCV13 breakthrough infections. Fewer PCV breakthrough infections occurred in the first year of life with 3 primary doses. Differences in breakthrough infection rates by schedule decreased as vaccine serotypes decreased in circulation.
Sections du résumé
BACKGROUND
Most countries use 3-dose pneumococcal conjugate vaccine (PCV) schedules; a 4-dose (3 primary and 1 booster) schedule is licensed for US infants. We evaluated the invasive pneumococcal disease (IPD) breakthrough infection incidence in children receiving 2 vs 3 primary PCV doses with and without booster doses (2 + 1 vs 3 + 1; 2 + 0 vs 3 + 0).
METHODS
We used 2001-2016 Active Bacterial Core surveillance data to identify breakthrough infections (vaccine-type IPD in children receiving ≥1 7-valent pneumococcal conjugate vaccine [PCV7] or 13-valent pneumococcal conjugate vaccine [PCV13] dose) among children aged <5 years. We estimated schedule-specific IPD incidence rates (IRs) per 100 000 person-years and compared incidence by schedule (2 + 1 vs 3 + 1; 2 + 0 vs 3 + 0) using rate differences (RDs) and incidence rate ratios.
RESULTS
We identified 71 PCV7 and 49 PCV13 breakthrough infections among children receiving a schedule of interest. PCV13 breakthrough infection rates were higher in children aged <1 year receiving the 2 + 0 (IR: 7.8) vs 3 + 0 (IR: 0.6) schedule (incidence rate ratio: 12.9; 95% confidence interval: 4.1-40.4); PCV7 results were similar. Differences in PCV13 breakthrough infection rates by schedule in children aged <1 year were larger in 2010-2011 (2 + 0 IR: 18.6; 3 + 0 IR: 1.4; RD: 16.6) vs 2012-2016 (2 + 0 IR: 3.6; 3 + 0 IR: 0.2; RD: 3.4). No differences between schedules were detected in children aged ≥1 year for PCV13 breakthrough infections.
CONCLUSIONS
Fewer PCV breakthrough infections occurred in the first year of life with 3 primary doses. Differences in breakthrough infection rates by schedule decreased as vaccine serotypes decreased in circulation.
Identifiants
pubmed: 32054822
pii: peds.2019-0836
doi: 10.1542/peds.2019-0836
pmc: PMC7055927
pii:
doi:
Substances chimiques
13-valent pneumococcal vaccine
0
Heptavalent Pneumococcal Conjugate Vaccine
0
Pneumococcal Vaccines
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 by the American Academy of Pediatrics.
Déclaration de conflit d'intérêts
POTENTIAL CONFLICT OF INTEREST: Dr Harrison has received fees from GlaxoSmithKline, Merck, Pfizer, and Sanofi Pasteur for consulting on the epidemiology and vaccine prevention of bacterial diseases; the other authors have indicated they have no potential conflicts of interest to disclose.
Références
MMWR Morb Mortal Wkly Rep. 2017 Nov 03;66(43):1171-1177
pubmed: 29095807
MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):258-61
pubmed: 20224542
Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S172-81
pubmed: 24336059
Vaccine. 2011 Dec 6;29(52):9600-6
pubmed: 21933696
Vaccine. 2011 Dec 6;29(52):9711-21
pubmed: 21821080
Vaccine. 2016 Apr 19;34(18):2062-5
pubmed: 26920471
Lancet Infect Dis. 2015 Mar;15(3):301-9
pubmed: 25656600
Wkly Epidemiol Rec. 2012 Apr 6;87(14):129-44
pubmed: 24340399
Lancet Respir Med. 2016 May;4(5):399-406
pubmed: 26987984
Pediatr Infect Dis J. 2015 Aug;34(8):875-83
pubmed: 26020410
Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S109-18
pubmed: 24336053
Lancet. 2006 Oct 28;368(9546):1495-502
pubmed: 17071283
Vaccine. 2015 Dec 16;33(51):7144-7151
pubmed: 26592141
Vaccine. 2016 Dec 7;34(50):6126-6132
pubmed: 27838066
Lancet Infect Dis. 2015 May;15(5):535-43
pubmed: 25801458
Pediatrics. 2010 Mar;125(3):429-36
pubmed: 20176669
Pediatr Infect Dis J. 2013 Mar;32(3):203-7
pubmed: 23558320
Clin Infect Dis. 2014 Oct 15;59(8):1066-73
pubmed: 25034421
Pediatrics. 2013 Aug;132(2):e324-32
pubmed: 23821695
Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S152-60
pubmed: 24336057
Clin Microbiol Infect. 2016 Jan;22(1):60.e9-60.e29
pubmed: 26363404
PLoS Med. 2013;10(9):e1001517
pubmed: 24086113
Emerg Infect Dis. 2015 Sep;21(9):1520-8
pubmed: 26292067
Vital Health Stat 1. 2017 Dec;(61):1-107
pubmed: 29466229
Vaccine. 2012 Jul 20;30(34):5132-40
pubmed: 22683519
J Infect Dis. 2008 Apr 1;197(7):1016-27
pubmed: 18419539
Clin Vaccine Immunol. 2010 Dec;17(12):1970-6
pubmed: 20943882
Pediatr Infect Dis J. 2010 May;29(5):401-5
pubmed: 20010312
J Infect Dis. 2010 Jan 1;201(1):32-41
pubmed: 19947881
Eur Respir J. 2016 Apr;47(4):1208-18
pubmed: 26797033
Pediatr Infect Dis J. 2012 Apr;31(4):392-9
pubmed: 22301472
Vaccine. 2003 Jul 4;21(23):3265-72
pubmed: 12804857
JAMA. 2013 Sep 4;310(9):930-7
pubmed: 24002279
Lancet Infect Dis. 2014 Sep;14(9):839-46
pubmed: 25042756
J Pediatr. 2010 Mar;156(3):478-483.e2
pubmed: 19962156
Vaccine. 2011 Apr 5;29(16):2999-3007
pubmed: 21320549
Pediatr Infect Dis J. 2015 Nov;34(11):1168-74
pubmed: 26226445
Pediatrics. 2014 Aug;134(2):210-7
pubmed: 25002663
N Engl J Med. 2014 Nov 13;371(20):1889-99
pubmed: 25386897
Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S119-29
pubmed: 24336054
MMWR Recomm Rep. 2000 Oct 6;49(RR-9):1-35
pubmed: 11055835